B cells as biomarkers: Predicting immune checkpoint therapy adverse events

Shannon M. Liudahl, Lisa M. Coussens

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations


Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that May be leveraged to improve patient monitoring and May prompt new treatment strategies to prevent IRAEs.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalJournal of Clinical Investigation
Issue number2
StatePublished - Feb 1 2018

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'B cells as biomarkers: Predicting immune checkpoint therapy adverse events'. Together they form a unique fingerprint.

Cite this